Management of Helicobacter pylori eradication--the influence of structured counselling and follow-up
- PMID: 11851640
- PMCID: PMC1874294
- DOI: 10.1046/j.0306-5251.2001.01531.x
Management of Helicobacter pylori eradication--the influence of structured counselling and follow-up
Abstract
Aims: Helicobacter pylori (H. pylori) eradication rate varies according to the treatment regimen used and other factors, e.g. antimicrobial resistance and patient compliance. The aim of the present study was to evaluate the influence of patient counselling and follow-up on H. pylori eradication rates and to document the effectiveness of a 1 week eradication regimen consisting of lansoprazole (30 mg once daily), amoxicillin (1 g twice daily) and clarithromycin (500 mg twice daily).
Methods: Seventy-six dyspeptic patients, who at endoscopy were found to have gastritis, duodenitis or ulceration, and a positive H. pylori urease test, were recruited. Patients were randomly assigned to an intervention group (n = 38) or a control group (n = 38). Intervention patients received their medicines via the hospital pharmacy and were counselled (and followed up) by a hospital pharmacist. Control patients were given a standard advice sheet and referred to their GP who prescribed the same therapy.
Results: Intervention patients exhibited a statistically significant improvement in the H. pylori eradication rate (94.7% vs 73.7%; P = 0.02) and compliance (92.1% vs 23.7; P < 0.001). Of the 64 H. pylori eradicated patients, 62 were able to eliminate their antisecretory medication compared with only 12 of the H. pylori persistent patients (P < 0.001). A pharmacoeconomic evaluation indicated that counselling and follow-up reduced the direct costs of eradication by approximately 30 UK pounds per patient.
Conclusions: Structured patient counselling and follow-up can have a significant effect on H. pylori eradication rates and should be a routine part of therapy.
Figures
Similar articles
-
EFFECT OF PHARMACIST COUNSELING ON PATIENT MEDICATION COMPLIANCE AND HELICOBACTER PYLORI ERADICATION AMONG JORDANIAN OUTPATIENTS.Arq Gastroenterol. 2023 Jan-Mar;60(1):74-83. doi: 10.1590/S0004-2803.202301000-10. Arq Gastroenterol. 2023. PMID: 37194783 Clinical Trial.
-
Decision analysis of Helicobacter pylori eradication therapy using omeprazole with either clarithromycin or amoxicillin.Pharmacoeconomics. 1996 Jul;10(1):79-92. doi: 10.2165/00019053-199610010-00008. Pharmacoeconomics. 1996. PMID: 10160472
-
Ten-day high-dose proton pump inhibitor triple therapy versus sequential therapy for Helicobacter pylori eradication.J Gastroenterol Hepatol. 2018 Nov;33(11):1822-1828. doi: 10.1111/jgh.14292. Epub 2018 Jun 27. J Gastroenterol Hepatol. 2018. PMID: 29804294 Clinical Trial.
-
Pharmacoeconomic comparison of Helicobacter pylori eradication regimens.Pharm World Sci. 2006 Aug;28(4):207-14. doi: 10.1007/s11096-006-9021-y. Epub 2006 Oct 26. Pharm World Sci. 2006. PMID: 17066247 Clinical Trial.
-
Twice daily short-message-based re-education could improve Helicobacter pylori eradication rate in young population: A prospective randomized controlled study.Helicobacter. 2019 Jun;24(3):e12569. doi: 10.1111/hel.12569. Epub 2019 Mar 8. Helicobacter. 2019. PMID: 30848868 Clinical Trial.
Cited by
-
Levofloxacin or Clarithromycin-based quadruple regimens: what is the best alternative as first-line treatment for Helicobacter pylori eradication in a country with high resistance rates for both antibiotics?BMC Gastroenterol. 2017 Feb 15;17(1):31. doi: 10.1186/s12876-017-0589-6. BMC Gastroenterol. 2017. PMID: 28202013 Free PMC article.
-
Application of a semi-automatic, intensive follow-up for improving efficacy and adherence of Helicobacter pylori eradication therapy: A randomized controlled trial.Microbiologyopen. 2021 Jan;10(1):e1172. doi: 10.1002/mbo3.1172. Microbiologyopen. 2021. PMID: 33650799 Free PMC article. Clinical Trial.
-
How to Effectively Use Bismuth Quadruple Therapy: The Good, the Bad, and the Ugly.Gastroenterol Clin North Am. 2015 Sep;44(3):537-63. doi: 10.1016/j.gtc.2015.05.003. Epub 2015 Jun 19. Gastroenterol Clin North Am. 2015. PMID: 26314667 Free PMC article. Review.
-
Assessment of pharmacist-led patient counseling in randomized controlled trials: a systematic review.Int J Clin Pharm. 2014 Oct;36(5):882-91. doi: 10.1007/s11096-014-9982-1. Epub 2014 Jul 23. Int J Clin Pharm. 2014. PMID: 25052621
-
Self-reported adverse drug effects and associated factors among H. pylori infected patients on standard triple therapy: Prospective follow up study.PLoS One. 2019 Nov 22;14(11):e0225585. doi: 10.1371/journal.pone.0225585. eCollection 2019. PLoS One. 2019. PMID: 31756217 Free PMC article.
References
-
- Bourke B, Sherman P, Drumm B. Peptic ulcer disease: what is the role for Helicobacter pylori. Semin Gastrointest Dis. 1994;5:24–31. - PubMed
-
- Sipporen P. Gastric cancer – A long term consequence of Helicobacter pylori infection? Scand J Gastroenterol. 1994;29(Suppl 201):24–27. - PubMed
-
- Sipporen P, Hyvarinen H. Role of Helicobacter pylori in the pathogensis of gastritis, peptic ulcer and gastric cancer. Scand J Gastroenterol. 1993;28(Suppl 196):3–6. - PubMed
-
- Bell GD, Powell KU, Burridge SM, et al. Rapid eradication of Helicobacter pylori infection. Aliment Pharmacol Ther. 1995;9:41–46. - PubMed
-
- The National Institute of Health Consensus Development Panel. Helicobacter pylori in peptic ulcer disease. JAMA. 1994;272:65–69. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical